Aduro moves a novel cancer immunotherapy into the clinic that resulted from a former TI Pharma project involving AMC and VUmc

Former TI Pharma project for a novel cancer immunotherapy moves into the clinic.

In 2007 AMC and VUmc, together with five other parties started a project called “TNF ligands to cancer” with the aim to develop antibodies against cancer. Less than two years later a first patent was filed on antibodies against APRIL, developed by BioNovion and the group of AMC researcher Jan Paul Medema.

BioNovion licensed the technology and later merged into Aduro BioTech that is now initiating a Phase 1/2 clinical trial with the anti-APRIL antibody, for the treatment of multiple myeloma.

Read here for more information.